The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?

被引：21

作者：

Franceschi, Enrico ^{[1
]}

Mura, Antonella ^{[1
]}

De Biase, Dario ^{[2
]}

Tallini, Giovanni ^{[3
]}

Pession, Annalisa ^{[2
]}

Foschini, Maria Pia ^{[4
]}

Danieli, Daniela ^{[5
]}

Pizzolitto, Stefano ^{[6
]}

Zunarelli, Elena ^{[7
]}

Lanza, Giovanni ^{[8
,9
]}

Bartolini, Daniela ^{[10
]}

Silini, Enrico Maria ^{[11
]}

Visani, Michela ^{[3
]}

Di Oto, Enrico ^{[12
]}

Tosoni, Alicia ^{[1
]}

Minichillo, Santino ^{[1
]}

Lamberti, Giuseppe ^{[1
]}

Lanese, Andrea ^{[1
]}

Paccapelo, Alexandro ^{[1
]}

Bartolini, Stefania ^{[1
]}

Brandes, Alba A. ^{[1
]}

机构：

[1] IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Azienda USL, Dept Med Oncol, Bologna, Italy

[2] Univ Bologna, AUSL Bologna, Mol Diagnost Unit, Dept Pharm & Biotechnol FaBiT, Bologna, Italy

[3] Univ Bologna, Sch Med, Azienda USL Bologna,Mol Diagnost Unit, Dept Med,Dipartimento Med Specialist Diagnost & S, Bologna, Italy

[4] Univ Bologna, Dept Biomed & Neuro Motor Sci, Anat Pathol M Malpighi, Bellaria Hosp, Bologna, Italy

[5] San Bortolo Hosp, Dept Pathol, Vicenza, Italy

[6] Santa Maria della Misericordia Hosp, Dept Pathol, Udine, Italy

[7] Univ Hosp, Dept Pathol, Modena, Italy

[8] S Anna Univ Hosp, Dept Pathol, Ferrara, Italy

[9] Univ Ferrara, Ferrara, Italy

[10] Bufalini Hosp, Dept Pathol, Cesena, Italy

[11] Univ Hosp Parma, Dept Pathol, Via Gramsci 14, I-43100 Parma, Italy

[12] Univ Bologna, Sect Anat Pathol, Dept Biomed & Neuromotor Sci, I-40139 Bologna, Italy

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 16期

关键词：

1pl9q co-deletion; IDH; 1/2; IDH mutation; low-grade gliomas; MGMTmethylation; NGS; surgery; treatment; RANDOMIZED-TRIAL; VINCRISTINE CHEMOTHERAPY; EUROPEAN ORGANIZATION; SURGICAL RESECTION; PROGNOSTIC-FACTORS; RADIATION-THERAPY; PLUS PROCARBAZINE; IDH2; MUTATIONS; TEMOZOLOMIDE; ADULT;

D O I：

10.2217/fon-2017-0634

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. Methods: We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. Results: 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and lp/19q co-deletion (p = 0.035) correlated with overall survival. Conclusion: Both clinical and molecular factors are essential to determine prognosis and treatment strategies.

引用

页码：1559 / 1567

页数：9

共 25 条

[1] Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study [J].

Baumert, Brigitta G. ;

Hegi, Monika E. ;

van den Bent, Martin J. ;

von Deimling, Andreas ;

Gorlia, Thierry ;

Hoang-Xuan, Khe ;

Brandes, Alba A. ;

Kantor, Guy ;

Taphoorn, Martin J. B. ;

Ben Hassel, Mohamed ;

Hartmann, Christian ;

Ryan, Gail ;

Capper, David ;

Kros, Johan M. ;

Kurscheid, Sebastian ;

Wick, Wolfgang ;

Enting, Roelien ;

Reni, Michele ;

Thiessen, Brian ;

Dhermain, Frederic ;

Bromberg, Jacoline E. ;

Feuvret, Loic ;

Reijneveld, Jaap C. ;

Chinot, Olivier ;

Gijtenbeek, Johanna M. M. ;

Rossiter, John P. ;

Dif, Nicolas ;

Balana, Carmen ;

Bravo-Marques, Jose ;

Clement, Paul M. ;

Marosi, Christine ;

Tzuk-Shina, Tzahala ;

Nordal, Robert A. ;

Rees, Jeremy ;

Lacombe, Denis ;

Mason, Warren P. ;

Stupp, Roger .

LANCET ONCOLOGY, 2016, 17 (11) :1521-1532

[2] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Cavallo, Giovanna ;

Reni, Michele ;

Franceschi, Enrico ;

Bonaldi, Laura ;

Bertorelle, Roberta ;

Gardiman, Marina ;

Ghimenton, Claudio ;

Iuzzolino, Paolo ;

Pession, Annalisa ;

Blatt, Valeria ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4746-4753

[3] Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma [J].

Buckner, Jan C. ;

Shaw, Edward G. ;

Pugh, Stephanie L. ;

Chakravarti, Arnab ;

Gilbert, Mark R. ;

Barger, Geoffrey R. ;

Coons, Stephen ;

Ricci, Peter ;

Bullard, Dennis ;

Brown, Paul D. ;

Stelzer, Keith ;

Brachman, David ;

Suh, John H. ;

Schultz, Christopher J. ;

Bahary, Jean-Paul ;

Fisher, Barbara J. ;

Kim, Harold ;

Murtha, Albert D. ;

Bell, Erica H. ;

Won, Minhee ;

Mehta, Minesh P. ;

Curran, Walter J., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (14) :1344-1355

[4] Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402 [J].

Cairncross, Gregory ;

Wang, Meihua ;

Shaw, Edward ;

Jenkins, Robert ;

Brachman, David ;

Buckner, Jan ;

Fink, Karen ;

Souhami, Luis ;

Laperriere, Normand ;

Curran, Walter ;

Mehta, Minesh .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :337-343

[5] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].

Cairncross, JG ;

Ueki, K ;

Zlatescu, MC ;

Lisle, DK ;

Finkelstein, DM ;

Hammond, RR ;

Silver, JS ;

Stark, PC ;

Macdonald, DR ;

Ino, Y ;

Ramsay, DA ;

Louis, DN .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479

[6] Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases [J].

Capelle, Laurent ;

Fontaine, Denys ;

Mandonnet, Emmanuel ;

Taillandier, Luc ;

Golmard, Jean Louis ;

Bauchet, Luc ;

Pallud, Johan ;

Peruzzi, Philippe ;

Baron, Marie Helene ;

Kujas, Michele ;

Guyotat, Jacques ;

Guillevin, Remi ;

Frenay, Marc ;

Taillibert, Sophie ;

Colin, Philippe ;

Rigau, Valerie ;

Vandenbos, Fanny ;

Pinelli, Catherine ;

Duffau, Hugues .

JOURNAL OF NEUROSURGERY, 2013, 118 (06) :1157-1168

[7] Monoclonal antibody specific for IDH1 R132H mutation [J].

Capper, David ;

Zentgraf, Hanswalter ;

Balss, Joerg ;

Hartmann, Christian ;

von Deimling, Andreas .

ACTA NEUROPATHOLOGICA, 2009, 118 (05) :599-601

[8] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].

Esteller, M ;

Garcia-Foncillas, J ;

Andion, E ;

Goodman, SN ;

Hidalgo, OF ;

Vanaclocha, V ;

Baylin, SB ;

Herman, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354

[9] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas [J].

Hartmann, Christian ;

Meyer, Jochen ;

Balss, Joerg ;

Capper, David ;

Mueller, Wolf ;

Christians, Arne ;

Felsberg, Joerg ;

Wolter, Marietta ;

Mawrin, Christian ;

Wick, Wolfgang ;

Weller, Michael ;

Herold-Mende, Christel ;

Unterberg, Andreas ;

Jeuken, Judith W. M. ;

Wesseling, Peter ;

Reifenberger, Guido ;

von Deimling, Andreas .

ACTA NEUROPATHOLOGICA, 2009, 118 (04) :469-474

[10] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

← 1 2 3 →